Journal
CANCER COMMUNICATIONS
Volume 39, Issue 1, Pages -Publisher
WILEY
DOI: 10.1186/s40880-019-0402-8
Keywords
Lung cancer; Drug resistance; Pathological transition
Categories
Funding
- National Basic Research Program of China [2017YFA0505501]
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19020201]
- National Natural Science Foundation of China [81430066, 91731314, 31621003, 81872312, 81871875, 81802279]
Ask authors/readers for more resources
Despite the tremendous efforts for improving therapeutics of lung cancer patients, its prognosis remains disappointing. This can be largely attributed to the lack of comprehensive understanding of drug resistance leading to insufficient development of effective therapeutics in clinic. Based on the current progresses of lung cancer research, we classify drug resistance mechanisms into three different levels: molecular, cellular and pathological level. All these three levels have significantly contributed to the acquisition and evolution of drug resistance in clinic. Our understanding on drug resistance mechanisms has begun to change the way of clinical practice and improve patient prognosis. In this review, we focus on discussing the pathological changes linking to drug resistance as this has been largely overlooked in the past decades.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available